LIBTAYO's robust efficacy in high-risk CSCC and potential blockbuster status ... There are presently 11 Phase III studies being explored in a diverse array of disease areas that may be further ...

With no currently approved options in the adjuvant setting, these landmark results demonstrate Libtayo could represent a major advance in delaying recurrence in these vulnerable patients.” C-POST ...

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Updated results from the study ... Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for an uncommon skin cancer called cutaneous squamous cell carcinoma ...

The C-POST study involved 415 patients ... in the first half of 2025. Libtayo is already established as a standard of care for certain patients with advanced CSCC. However, its potential new ...

The C-POST study involved 415 patients who were ... in the first half of 2025. Libtayo is already established as a standard of care for certain patients with advanced CSCC. However, its potential new ...